Trupanion (TRUP) 10-Q 31 Jul 19 2019 Q2 Quarterly report Financial data

Cover Page Document

Cover Page Document - shares	6 Months Ended
	Jun. 30, 2019	Jul. 23, 2019
Cover Page [Abstract]
Entity Central Index Key	0001371285
Entity Common Stock, Shares Outstanding		34,790,142
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common stock, $0.00001 par value per share
City Area Code	(855)
Entity Address, Address Line One	6100 4th Avenue S, Suite 200
Entity Address, City or Town	Seattle,
Entity Incorporation, State or Country Code	DE
Document Period End Date	Jun. 30, 2019
Document Transition Report	false
Document Quarterly Report	true
Entity File Number	001-36537
Entity Tax Identification Number	83-0480694
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98108
Local Phone Number	727 - 9079
Trading Symbol	TRUP
Security Exchange Name	NASDAQ
Entity Small Business	false
Entity Emerging Growth Company	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Registrant Name	TRUPANION, INC.

Consolidated Statement of Opera

Consolidated Statement of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenue	$ 92,199	$ 73,392	$ 179,177	$ 143,152
Cost of Revenue [Abstract]
Veterinary invoice expense	65,933	51,780	127,215	101,893
Other Cost of Services Sold	11,553	9,259	22,217	17,842
Gross profit	14,713	12,353	29,745	23,417
Operating Expenses [Abstract]
Technology and Development Expense	2,578	2,298	5,247	4,462
General and Administrative Expense	5,219	4,610	10,638	9,068
Selling and Marketing Expense	8,757	5,702	16,984	11,640
Operating Expenses	16,554	12,610	32,869	25,170
Income (Loss) from Equity Method Investments	(272)		(272)
Operating loss	(2,113)	(257)	(3,396)	(1,753)
Interest expense	317	332	634	551
Other income, net	(453)	(303)	(797)	(443)
Income (Loss) before income taxes	(1,977)	(286)	(3,233)	(1,861)
Income tax (benefit) expense	(46)	91	(6)	(4)
Net loss	$ (1,931)	$ (377)	$ (3,227)	$ (1,857)
Earnings Per Share, Basic and Diluted	$ (0.06)	$ (0.01)	$ (0.09)	$ (0.06)
Weighted Average Number of Shares Outstanding, Basic and Diluted	34,610,709	30,721,037	34,450,070	30,485,121

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income Statement - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (1,931)	$ (377)	$ (3,227)	$ (1,857)
Foreign currency translation adjustments	138	(129)	328	(319)
Net unrealized gain on available-for-sale debt securities	0	15	18	0
Other comprehensive income (loss), net of taxes	138	(114)	346	(319)
Comprehensive Income (Loss)	$ (1,793)	$ (491)	$ (2,881)	$ (2,176)

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets [Abstract]
Cash and cash equivalents	$ 27,379	$ 26,552
Short-term Investments	64,712	54,559
Accounts and other receivables	43,550	31,565
Prepaid expenses and other assets	4,322	5,300
Total current assets	139,963	117,976
Restricted Cash	1,400	1,400
Long-Term Investments, at fair value	3,891	3,554
Property and equipment, net	69,371	69,803
Intangible assets, net	7,631	8,071
Other Long-Term Assets	8,208	6,706
Total assets	230,464	207,510
Liabilities and Equity [Abstract]
Accounts payable	2,117	2,767
Accrued liabilities and other current liabilities	13,390	11,347
Reserve for veterinary invoices	18,280	16,062
Deferred Revenue	44,086	33,027
Total current liabilities	77,873	63,203
Long-term debt	19,056	12,862
Deferred tax liabilities	1,014	1,002
Other liabilities	1,498	1,270
Total liabilities	99,441	78,337
Common stock	0	0
Preferred Stock	0	0
Additional paid-in capital	229,069	219,838
Accumulated other comprehensive loss	(407)	(753)
Accumulated deficit	(86,938)	(83,711)
Treasury stock, at cost	(10,701)	(6,201)
Stockholders' Equity Attributable to Parent	131,023	129,173
Total liabilities and stockholders' equity	$ 230,464	$ 207,510

Consolidated Balance Sheet Cond

Consolidated Balance Sheet Condensed Consolidated Balance Sheet Parentheticals - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	35,712,189	34,781,121
Common Stock, Shares, Outstanding	34,782,324	34,025,136
Preferred Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	929,865	755,985

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]
Common Stock, Shares, Outstanding		30,121,496
Stockholders' Equity Attributable to Parent	$ 48,434	$ 0	$ 134,511	$ (82,784)	$ (92)	$ (3,201)
Redemption of warrants		30,000
Settlement of warrant liabilities	300		300			0
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings		167,466
Stock Issued During Period, Shares, New Issues		2,090,909
Proceeds from issuance of common stock, follow-on public offering	65,689		65,689
Redemption of warrants		231,315
Settlement of warrant liabilities	300		3,300			(3,000)
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings		275,570
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings	1,656		1,656
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	2,349		2,349
Other Comprehensive Income (Loss), Net of Tax	(319)				(319)
Net Income (Loss) Available to Common Stockholders, Basic	$ (1,857)			(1,857)
Stock Issued During Period, Shares, New Issues	2,090,909
Common Stock, Shares, Outstanding		30,430,915
Stockholders' Equity Attributable to Parent	$ 48,247	$ 0	139,009	(84,264)	(297)	(6,201)
Stock Issued During Period, Shares, New Issues		2,090,909
Proceeds from issuance of common stock, follow-on public offering	65,689		65,689
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings	1,175		1,175
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	1,332		1,332
Other Comprehensive Income (Loss), Net of Tax	(114)				(114)
Net Income (Loss) Available to Common Stockholders, Basic	(377)			(377)
Common Stock, Shares, Outstanding		32,719,290
Stockholders' Equity Attributable to Parent	$ 116,252	$ 0	207,505	(84,641)	(411)	(6,201)
Common Stock, Shares, Outstanding	34,025,136	34,025,136
Stockholders' Equity Attributable to Parent	$ 129,173	$ 0	219,838	(83,711)	(753)	(6,201)
Redemption of warrants		30,000
Settlement of warrant liabilities	$ 300		300			0
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings		284,859
Redemption of warrants	480,000	306,120
Settlement of warrant liabilities	$ 300		4,800			(4,500)
Stock Issued During Period, Shares, Share-based Compensation, Net of Tax Withholdings		451,068
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings	1,092		1,092
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	3,339		3,339
Other Comprehensive Income (Loss), Net of Tax	346				346
Net Income (Loss) Available to Common Stockholders, Basic	(3,227)			(3,227)
Common Stock, Shares, Outstanding		34,467,465
Stockholders' Equity Attributable to Parent	130,009	$ 0	226,262	(85,007)	(545)	(10,701)
Stock Issued During Period, Value, Share-based Compensation, Net of Tax Withholdings	585		585
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	1,922		1,922
Other Comprehensive Income (Loss), Net of Tax	138				138
Net Income (Loss) Available to Common Stockholders, Basic	$ (1,931)			(1,931)
Common Stock, Shares, Outstanding	34,782,324	34,782,324
Stockholders' Equity Attributable to Parent	$ 131,023	$ 0	$ 229,069	$ (86,938)	$ (407)	$ (10,701)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic	$ (1,931)	$ (377)	$ (3,227)	$ (1,857)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and Amortization			3,177	1,891
Stock-based compensation expense			3,230	2,254
Other, Net			97	38
Increase (Decrease) in Operating Assets [Abstract]
Accounts and other receivables			11,940	8,168
Prepaid expenses and other assets			(989)	4,068
Accounts Payable, Accrued Liabilities, and Other Liabilities			1,443	2,567
Claims Reserve			2,145	1,293
Deferred revenue			10,967	7,661
Net cash provided by operating activities			6,881	1,611
Net Cash Provided by Investing Activities [Abstract]
Payments to Acquire Investments			(32,222)	(20,386)
Maturities of Investment Securities			21,895	15,015
Purchases of property and equipment			(1,780)	(2,370)
Payments for (Proceeds from) Other Investing Activities			(1,474)	113
Net cash used in investing activities			(13,581)	(7,628)
Net Cash Provided by Financing Activities [Abstract]
Proceeds from Issuance or Sale of Equity			0	65,886	$ 65,700
Proceeds from exercise of stock options			1,626	1,656
Payments Related to Tax Withholding for Share-based Compensation			(247)	0
Proceeds from Debt, Net of Issuance Costs			6,167	9,250
Proceeds from (Payments for) Other Financing Activities			(415)	(56)
Net cash provided by financing activities			7,131	76,736
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net			396	(201)
Net Increase in Cash, Cash Equivalents, and Restricted Cash			827	70,518
Cash, Cash Equivalents, and Restricted Cash at beginning of period			27,952	26,306	$ 26,306
Cash, Cash Equivalents, and Restricted Cash, End of Period	$ 28,779	$ 96,824	28,779	96,824
Supplemental Cash Flow Information [Abstract]
Redemption of Warrants Non-Cash; Common Stock			4,500	3,000
Purchases of property and equipment included in accounts payable and accrued liabilities			$ 637	$ 153

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	Nature of Operations and Significant Accounting Policies Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2018 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 14, 2019 (the 2018 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2018 10-K. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2018 10-K for additional discussion of these estimates and assumptions. Recently Adopted Accounting Pronouncements The Company adopted Accounting Standards Update (ASU) No. 2016-02 Leases (Topic 842), as amended, using the modified retrospective approach under which the transition provisions were applied as of January 1, 2019. In addition, the Company elected the “package of practical expedients” under the transition guidance within the new standard to not reassess prior conclusions about lease identification, lease classification, and initial direct costs for existing lease contracts. The Company also elected the practical expedient to not separate lease and non-lease components, if any, for all lease contracts. Upon adoption of this standard, the Company recorded approximately $0.1 million right-of-use assets and lease liabilities for operating leases. They were classified as other long-term assets and other liabilities on the Company's consolidated balance sheets. The standard did not have a material impact on the Company's consolidated statements of operations, stockholders' equity, or cash flows. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued an ASU amending the measurement of credit losses on financial instruments. The ASU requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period, with early adoption permitted. The Company is currently in the process of evaluating the impact the adoption of this ASU will have on its consolidated financial statements. In August 2018, the FASB issued an ASU that eliminates certain disclosure requirements for fair value measurements, requires new disclosures regarding significant unobservable inputs used to develop Level 3 fair value measurements, and modifies certain existing disclosure requirements for Level 3 fair value measurements. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period, with early adoption permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share, Basic and Diluted [Abstract]
Earnings Per Share [Text Block]	Net Income (Loss) per Share Basic net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated using the weighted average number of shares of common stock plus, when dilutive, potential shares of common stock outstanding using the treasury-stock method. Potential shares of common stock outstanding include stock options, unvested restricted stock awards and restricted stock units, and warrants. The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Stock options 2,253,995 3,696,242 2,253,995 3,696,242 Restricted stock awards and restricted stock units 715,941 555,984 715,941 555,984 Warrants — 480,000 — 480,000

Investment Securities (Notes)

Investment Securities (Notes)	6 Months Ended
	Jun. 30, 2019
Investments [Abstract]
Investment [Text Block]	The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of June 30, 2019 and December 31, 2018 (in thousands): Amortized Gross Gross Fair As of June 30, 2019 Long-term investments: Foreign deposits $ 2,891 $ — $ — $ 2,891 Municipal bond 1,000 — — 1,000 $ 3,891 $ — $ — $ 3,891 Short-term investments: U.S. Treasury securities $ 6,140 $ 4 $ — $ 6,144 Certificates of deposit 439 — — 439 U.S. government funds 58,133 — — 58,133 $ 64,712 $ 4 $ — $ 64,716 Amortized Gross Gross Fair As of December 31, 2018 Long-term investments: Foreign deposits $ 2,573 $ — $ — $ 2,573 Municipal bond 1,000 — (19 ) 981 $ 3,573 $ — $ (19 ) $ 3,554 Short-term investments: U.S. Treasury securities $ 6,645 $ — $ (3 ) $ 6,642 Certificates of deposit 437 — — 437 U.S. government funds 47,477 — — 47,477 $ 54,559 $ — $ (3 ) $ 54,556 Maturities of debt securities classified as available-for-sale were as follows (in thousands): As of June 30, 2019 Amortized Fair Available-for-sale: Due after one year through five years $ 3,891 $ 3,891 $ 3,891 $ 3,891 The Company evaluated its securities for other-than-temporary impairment and considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. For debt securities, the Company does not intend to sell, nor is it more likely than not that the Company will be required to sell, the securities prior to maturity or prior to the recovery of the amortized cost basis.
Investments [Text Block]	The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of June 30, 2019 and December 31, 2018 (in thousands): Amortized Gross Gross Fair As of June 30, 2019 Long-term investments: Foreign deposits $ 2,891 $ — $ — $ 2,891 Municipal bond 1,000 — — 1,000 $ 3,891 $ — $ — $ 3,891 Short-term investments: U.S. Treasury securities $ 6,140 $ 4 $ — $ 6,144 Certificates of deposit 439 — — 439 U.S. government funds 58,133 — — 58,133 $ 64,712 $ 4 $ — $ 64,716 Amortized Gross Gross Fair As of December 31, 2018 Long-term investments: Foreign deposits $ 2,573 $ — $ — $ 2,573 Municipal bond 1,000 — (19 ) 981 $ 3,573 $ — $ (19 ) $ 3,554 Short-term investments: U.S. Treasury securities $ 6,645 $ — $ (3 ) $ 6,642 Certificates of deposit 437 — — 437 U.S. government funds 47,477 — — 47,477 $ 54,559 $ — $ (3 ) $ 54,556

Other Investments (Notes)

Other Investments (Notes)	6 Months Ended
	Jun. 30, 2019
Investments, All Other Investments [Abstract]
Investments and Other Noncurrent Assets [Text Block]	Other Investments Investment in Variable Interest Entity In July 2018, the Company purchased $3.0 million in preferred stock of a privately held corporation with a complementary business line. The Company does not have power over the activities that most significantly impact the economic performance of the variable interest entity and is, therefore, not the primary beneficiary. The Company's investment in preferred stock is accounted for as an available-for-sale debt security. Through January 2020, the Company has agreed to purchase an additional $4.0 million in preferred stock of the variable interest entity, contingent upon the exercise of this option by the variable interest entity. The Company has the option to purchase the variable interest entity on the fifth anniversary of the initial preferred stock purchase. Additionally, the Company has extended a $2.5 million revolving line of credit to the variable interest entity. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. Outstanding loan balance under the line of credit was $2.1 million and $0.6 million as of June 30, 2019 and December 31, 2018, respectively. Investment in Joint Venture In September 2018, the Company acquired a non-controlling equity interest in a joint venture, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of June 30, 2019, the Company has contributed $0.3 million

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Fair Value Investments The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of June 30, 2019 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 2,038 2,038 — — Fixed maturities: Foreign deposits 2,891 2,891 — — Municipal bond 1,000 — 1,000 — Investment in variable interest entity 3,000 — — 3,000 Total $ 10,329 $ 6,329 $ 1,000 $ 3,000 As of December 31, 2018 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 2,010 2,010 — — Fixed maturities: Foreign deposits 2,573 2,573 — — Municipal bond 981 — 981 — Investment in variable interest entity 3,000 — — 3,000 Total $ 9,964 $ 5,983 $ 981 $ 3,000 The Company measures the fair value of restricted cash, money market funds, and foreign deposits based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The estimated fair value of the Company's investment in the variable interest entity is a Level 3 measurement, and is based on market interest rates, the assessed creditworthiness of the entity, and the estimated fair value of the entity's common stock. As of June 30, 2019 , the Company estimates that the purchase price approximates the fair value. There were no transfers in or out of Level 3 assets during the six months ended June 30, 2019. Short-term investments are carried at amortized cost and the fair value is disclosed in Note 3, Investments. The fair value of these investments is determined in the same manner as for available-for-sale securities and is considered a Level 1 measurement. Fair Value Disclosures The Company's other long-term assets balance included $4.4 million of notes receivable as of June 30, 2019 and $3.0 million of notes receivable as of December 31, 2018, recorded at its estimated collectible amount. The Company estimates that the carrying value of the note receivable approximates its fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of its long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at June 30, 2019 and December 31, 2018 .

Debt

Debt	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Debt The Company has a revolving line of credit of up to $50.0 million , maturing June 2022. The facility is secured by any and all interests in the Company's assets that are not otherwise restricted. Interest on the revolving line of credit is payable monthly at the greater of 4.5%, or 0.75% plus the prime rate ( 6.25% at June 30, 2019 ). The credit agreement includes other ancillary services and letters of credit of up to $4.5 million , and requires a deposit of restricted cash of $1.4 million . The credit agreement requires the Company to comply with various financial and non-financial covenants. As of June 30, 2019 , the Company was in compliance with all financial and non-financial covenants required by the credit agreement. Borrowings on the revolving line of credit are limited to the lesser of $50.0 million and the total amount of cash and securities held by the Company's insurance subsidiaries (American Pet Insurance Company and Wyndham Insurance Company (SAC) Limited Segregated Account AX). As of June 30, 2019 , available borrowing capacity on the line of credit was $30.3 million , with an outstanding balance of $0.5 million for ancillary services and letters of credit, and borrowings under the facility of $19.2 million , recorded net of financing fees of $0.1 million

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Certain state insurance regulators in the United States have contacted the Company regarding whether employees who had helped prospective members enroll by telephone in prior years were required to have an insurance license to conduct such telephone conversations. To date, the Company has resolved each of these matters in non-material amounts and believes it is compliant with the applicable regulations. The Company is currently engaged with a limited number of state insurance regulators to resolve this same legacy issue and believes it has adequately reserved for these matters. In addition, from time to time the Company is or may become subject to various legal proceedings arising in the ordinary course of business, including proceedings against members, other entities or regulatory bodies. Estimated liabilities are recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. At this time, the Company does not believe any such matters to be material individually or in the aggregate. These views are subject to change following the outcome of future events or the results of future developments.

Claims Reserve

Claims Reserve	6 Months Ended
	Jun. 30, 2019
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Disclosure [Text Block]	Reserve for Veterinary Invoices The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense. Reserve for veterinary invoices Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Six Months Ended June 30, Subscription 2019 2018 Reserve at beginning of year $ 13,875 $ 11,059 Veterinary invoices during the period related to: Current year 110,248 91,464 Prior years 551 119 Total veterinary invoice expense 110,799 91,583 Amounts paid during the period related to: Current year 97,165 80,841 Prior years 11,364 9,256 Total paid 108,529 90,097 Non-cash expenses 369 333 Reserve at end of period $ 15,776 $ 12,212 The Company's reserve for the subscription business segment increased from $13.9 million at December 31, 2018 to $15.8 million at June 30, 2019 . This change was comprised of $110.8 million in expense recorded during the period less $108.5 million in payments of veterinary invoices. The $110.8 million in veterinary invoice expense incurred included an adjustment of $0.6 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2018 , the Company increased prior year reserves by $0.1 million as a result of analysis of payment trends. Summarized below are the changes in total liability for the Company's other business segment (in thousands): Six Months Ended June 30, Other Business 2019 2018 Reserve at beginning of year $ 2,187 $ 1,697 Veterinary invoices during the period related to: Current year 16,747 10,589 Prior years (331 ) (279 ) Total veterinary invoice expense 16,416 10,310 Amounts paid during the period related to: Current year 14,431 8,916 Prior years 1,668 1,307 Total paid 16,099 10,223 Non-cash expenses — — Reserve at end of period $ 2,504 $ 1,784 The Company’s reserve for the other business segment increased from $2.2 million at December 31, 2018 to $2.5 million at June 30, 2019 . This change was comprised of $16.4 million in expense recorded during the period less $16.1 million in payments of veterinary invoices. The $16.4 million in veterinary invoice expense incurred included a reduction of $0.3 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2018 , the Company decreased prior year reserves by $0.3 million as a result of analysis of payment trends. Reserve for veterinary invoices, by year of occurrence In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by the year to which the veterinary invoice relates, referred to as the year of occurrence. Subscription As of June 30, 2019 Year of Occurrence 2017 and prior $ 862 2018 2,201 2019 12,713 $ 15,776 Other Business As of June 30, 2019 Year of Occurrence 2017 and prior $ 9 2018 179 2019 2,316 $ 2,504

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Stock-Based Compensation Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and other service providers and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Veterinary invoice expense $ 185 $ 148 $ 346 $ 268 Other cost of revenue 93 104 179 181 Technology and development 110 60 173 109 General and administrative 918 625 1,536 1,074 Sales and marketing 567 349 996 622 Total stock-based compensation $ 1,873 $ 1,286 $ 3,230 $ 2,254 As of June 30, 2019 , the Company had 323,257 unvested stock options and 715,941 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expenses of $2.2 million related to unvested stock options and $16.2 million related to unvested restricted stock awards and restricted stock units are expected to be recognized over a weighted average period of approximately 1.6 years and 2.7 years, respectively. Stock Options A summary of the Company's stock option activity is as follows: Number of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2018 2,621,503 $ 9.01 $ 43,136 Granted — — — Exercised (361,653 ) 3.65 9,736 Forfeited (5,855 ) 17.79 — Outstanding as of June 30, 2019 2,253,995 9.85 59,245 Exercisable as of June 30, 2019 1,930,738 $ 8.67 $ 53,019 As of June 30, 2019 , stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 5.6 years and 5.2 years, respectively. Restricted Stock Awards and Restricted Stock Units A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2018 451,160 $ 22.16 Granted 374,348 29.88 Vested (97,735 ) 27.92 Forfeited (11,832 ) 28.07 Unvested shares as of June 30, 2019 715,941 $ 25.31

Leases (Notes)

Leases (Notes)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases of Lessor Disclosure [Text Block]	Leases The Company leases certain office space and equipment from third parties and recognizes lease expense on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on its consolidated balance sheets. The Company also leases a portion of its building to third parties and records related rental income within general and administrative expense in the consolidated statements of operations. These leases have remaining initial lease terms of 2 years to 8 years, some of which give the tenants options to renew the leases for up to an additional 10 years, and options to terminate the leases after 3 years of the initial lease terms, with early termination fees required. The Company recorded rental income of $1.1 million for the six months ended June 30, 2019 . The following table summarizes the Company's future rental payments to be received from non-cancellable leases in place as of June 30, 2019 (in thousands): Year ending December 31: 2019 $ 1,071 2020 1,982 2021 1,558 2022 1,173 2023 1,210 Thereafter 2,762 Total rental payments $ 9,756

Stockholders' Equity (Notes)

Stockholders' Equity (Notes)	6 Months Ended
	Jun. 30, 2019
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Stockholders' Equity As of June 30, 2019 , the Company had 100,000,000 shares of common stock authorized and 34,782,324 shares of common stock outstanding. Holders of common stock are entitled to one vote on each matter properly submitted to the stockholders of the Company except those related to matters concerning possible outstanding preferred stock. At June 30, 2019 , the Company had 10,000,000 shares of undesignated preferred stock authorized for future issuance and did not have any outstanding shares of preferred stock. The holders of common stock are also entitled to receive dividends as and when declared by the board of directors of the Company, whenever funds are legally available. These rights are subordinate to the dividend rights of holders of any senior classes of stock outstanding at the time. The Company is unable to pay dividends to stockholders as of June 30, 2019 due to restrictions in its credit agreements. In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.7 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. The proceeds were primarily used to purchase real estate consisting of properties in use as the Company's home office. In addition, in August 2018, the Company issued 303,030 shares of common stock via a private placement to an accredited investor as a portion of the purchase price of the real estate. During the six months ended June 30, 2019 , outstanding warrants to purchase 480,000 shares of the Company's common stock were exercised. As of June 30, 2019 , no warrants remained outstanding.

Segments

Segments	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Segments The Company has two segments: subscription business and other business. The subscription business segment includes revenue and expenses related to monthly subscriptions for the Company’s medical insurance that is marketed directly to consumers, while the other business segment includes all revenue and expenses related to the Company's business that is not directly marketed to consumers. The chief operating decision maker primarily uses two measures to evaluate segment GAAP financial performance: revenue and gross profit. Additionally, other operating expenses, such as sales and marketing expenses, are allocated to each segment and evaluated when material. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets. Revenue and gross profit of the Company’s segments were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Revenue: Subscription business $ 77,736 $ 63,867 $ 151,958 $ 125,384 Other business 14,463 9,525 27,219 17,768 92,199 73,392 179,177 143,152 Veterinary invoice expense: Subscription business 57,161 46,446 110,799 91,583 Other business 8,772 5,334 16,416 10,310 65,933 51,780 127,215 101,893 Other cost of revenue: Subscription business 7,103 5,887 13,852 11,764 Other business 4,450 3,372 8,365 6,078 11,553 9,259 22,217 17,842 Gross profit: Subscription business 13,472 11,534 27,307 22,037 Other business 1,241 819 2,438 1,380 14,713 12,353 29,745 23,417 Technology and development 2,578 2,298 5,247 4,462 General and administrative 5,219 4,610 10,638 9,068 Sales and marketing: Subscription business 8,719 5,614 16,816 11,465 Other business 38 88 168 175 8,757 5,702 16,984 11,640 Gain (loss) from investment in joint venture (272 ) — (272 ) — Operating loss $ (2,113 ) $ (257 ) $ (3,396 ) $ (1,753 ) The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 United States $ 75,930 $ 59,431 $ 147,087 $ 115,440 Canada 16,269 13,961 32,090 27,712 Total revenue $ 92,199 $ 73,392 $ 179,177 $ 143,152 Substantially all of the Company’s long-lived assets were located in the United States as of June 30, 2019 and December 31, 2018 .

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2018 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 14, 2019 (the 2018 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2018 10-K. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2018 10-K for additional discussion of these estimates and assumptions.
Basis of Accounting, Policy [Policy Text Block]	The financial data as of December 31, 2018 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 14, 2019 (the 2018 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2018 10-K. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2018 10-K for additional discussion of these estimates and assumptions.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements The Company adopted Accounting Standards Update (ASU) No. 2016-02 Leases (Topic 842), as amended, using the modified retrospective approach under which the transition provisions were applied as of January 1, 2019. In addition, the Company elected the “package of practical expedients” under the transition guidance within the new standard to not reassess prior conclusions about lease identification, lease classification, and initial direct costs for existing lease contracts. The Company also elected the practical expedient to not separate lease and non-lease components, if any, for all lease contracts. Upon adoption of this standard, the Company recorded approximately $0.1 million right-of-use assets and lease liabilities for operating leases. They were classified as other long-term assets and other liabilities on the Company's consolidated balance sheets. The standard did not have a material impact on the Company's consolidated statements of operations, stockholders' equity, or cash flows. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued an ASU amending the measurement of credit losses on financial instruments. The ASU requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period, with early adoption permitted. The Company is currently in the process of evaluating the impact the adoption of this ASU will have on its consolidated financial statements. In August 2018, the FASB issued an ASU that eliminates certain disclosure requirements for fair value measurements, requires new disclosures regarding significant unobservable inputs used to develop Level 3 fair value measurements, and modifies certain existing disclosure requirements for Level 3 fair value measurements. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period, with early adoption permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements.

Other Investments Investment in

Other Investments Investment in Variable Interest Entity (Policies)	6 Months Ended
	Jun. 30, 2019
Investments, All Other Investments [Abstract]
Variable Interest Entity Disclosure [Text Block]	Investment in Variable Interest Entity In July 2018, the Company purchased $3.0 million in preferred stock of a privately held corporation with a complementary business line. The Company does not have power over the activities that most significantly impact the economic performance of the variable interest entity and is, therefore, not the primary beneficiary. The Company's investment in preferred stock is accounted for as an available-for-sale debt security. Through January 2020, the Company has agreed to purchase an additional $4.0 million in preferred stock of the variable interest entity, contingent upon the exercise of this option by the variable interest entity. The Company has the option to purchase the variable interest entity on the fifth anniversary of the initial preferred stock purchase. Additionally, the Company has extended a $2.5 million revolving line of credit to the variable interest entity. The Company's investment and amounts loaned under the line of credit are recorded in other long-term assets on its consolidated balance sheet. Outstanding loan balance under the line of credit was $2.1 million and $0.6 million as of June 30, 2019 and December 31, 2018, respectively.

Other Investments Investment _2

Other Investments Investment in Joint Venture (Policies)	6 Months Ended
	Jun. 30, 2019
Investments, All Other Investments [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Investment in Joint Venture In September 2018, the Company acquired a non-controlling equity interest in a joint venture, whereby it has committed to licensing certain intellectual property and contributing up to $2.2 million AUD upon the achievement of specific operational milestones over a period of at least four years from the agreement execution date. As of June 30, 2019, the Company has contributed $0.3 million

Fair Value Notes Receivable (Po

Fair Value Notes Receivable (Policies)	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	The Company's other long-term assets balance included $4.4 million of notes receivable as of June 30, 2019 and $3.0 million of notes receivable as of December 31, 2018, recorded at its estimated collectible amount. The Company estimates that the carrying value of the note receivable approximates its fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of its long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at June 30, 2019 and December 31, 2018 .

Fair Value Fair Value (Policies

Fair Value Fair Value (Policies)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments, Policy [Policy Text Block]	The Company measures the fair value of restricted cash, money market funds, and foreign deposits based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The estimated fair value of the Company's investment in the variable interest entity is a Level 3 measurement, and is based on market interest rates, the assessed creditworthiness of the entity, and the estimated fair value of the entity's common stock. As of June 30, 2019 , the Company estimates that the purchase price approximates the fair value. There were no transfers in or out of Level 3 assets during the six months ended June 30, 2019. Short-term investments are carried at amortized cost and the fair value is disclosed in Note 3, Investments. The fair value of these investments is determined in the same manner as for available-for-sale securities and is considered a Level 1 measurement.

Claims Reserve Claims Reserve (

Claims Reserve Claims Reserve (Policies)	6 Months Ended
	Jun. 30, 2019
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
Liability Reserve Estimate, Policy [Policy Text Block]	Reserve for Veterinary Invoices The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns. The Company uses generally accepted actuarial methodologies, such as paid loss development methods, in estimating the amount of the reserve for veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and is continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense.

Segments Segments (Policies)

Segments Segments (Policies)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Segment Reporting, Policy [Policy Text Block]	The Company has two segments: subscription business and other business. The subscription business segment includes revenue and expenses related to monthly subscriptions for the Company’s medical insurance that is marketed directly to consumers, while the other business segment includes all revenue and expenses related to the Company's business that is not directly marketed to consumers. The chief operating decision maker primarily uses two measures to evaluate segment GAAP financial performance: revenue and gross profit. Additionally, other operating expenses, such as sales and marketing expenses, are allocated to each segment and evaluated when material. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets.

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share, Basic and Diluted [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following potentially dilutive equity securities were not included in the diluted earnings per share of common stock calculation because they would have had an antidilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Stock options 2,253,995 3,696,242 2,253,995 3,696,242 Restricted stock awards and restricted stock units 715,941 555,984 715,941 555,984 Warrants — 480,000 — 480,000

Investment Securities Available

Investment Securities Available-for-Sale (Tables)	6 Months Ended
	Jun. 30, 2019
Investments [Abstract]
Investment [Table Text Block]	The amortized cost, gross unrealized holding gains and losses, and estimates of fair value of long-term and short-term investments by major security type and class of security were as follows as of June 30, 2019 and December 31, 2018 (in thousands): Amortized Gross Gross Fair As of June 30, 2019 Long-term investments: Foreign deposits $ 2,891 $ — $ — $ 2,891 Municipal bond 1,000 — — 1,000 $ 3,891 $ — $ — $ 3,891 Short-term investments: U.S. Treasury securities $ 6,140 $ 4 $ — $ 6,144 Certificates of deposit 439 — — 439 U.S. government funds 58,133 — — 58,133 $ 64,712 $ 4 $ — $ 64,716 Amortized Gross Gross Fair As of December 31, 2018 Long-term investments: Foreign deposits $ 2,573 $ — $ — $ 2,573 Municipal bond 1,000 — (19 ) 981 $ 3,573 $ — $ (19 ) $ 3,554 Short-term investments: U.S. Treasury securities $ 6,645 $ — $ (3 ) $ 6,642 Certificates of deposit 437 — — 437 U.S. government funds 47,477 — — 47,477 $ 54,559 $ — $ (3 ) $ 54,556
Available-for-sale Securities [Table Text Block]	Maturities of debt securities classified as available-for-sale were as follows (in thousands): As of June 30, 2019 Amortized Fair Available-for-sale: Due after one year through five years $ 3,891 $ 3,891 $ 3,891 $ 3,891

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair value, asset & liabilities measured on recurring basis [Table Text Block]	The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of June 30, 2019 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 2,038 2,038 — — Fixed maturities: Foreign deposits 2,891 2,891 — — Municipal bond 1,000 — 1,000 — Investment in variable interest entity 3,000 — — 3,000 Total $ 10,329 $ 6,329 $ 1,000 $ 3,000 As of December 31, 2018 Fair Value Level 1 Level 2 Level 3 Assets Restricted cash $ 1,400 $ 1,400 $ — $ — Money market funds 2,010 2,010 — — Fixed maturities: Foreign deposits 2,573 2,573 — — Municipal bond 981 — 981 — Investment in variable interest entity 3,000 — — 3,000 Total $ 9,964 $ 5,983 $ 981 $ 3,000 The Company measures the fair value of restricted cash, money market funds, and foreign deposits based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. The estimated fair value of the Company's investment in the variable interest entity is a Level 3 measurement, and is based on market interest rates, the assessed creditworthiness of the entity, and the estimated fair value of the entity's common stock. As of June 30, 2019 , the Company estimates that the purchase price approximates the fair value. There were no transfers in or out of Level 3 assets during the six months ended June 30, 2019. Short-term investments are carried at amortized cost and the fair value is disclosed in Note 3, Investments. The fair value of these investments is determined in the same manner as for available-for-sale securities and is considered a Level 1 measurement.

Claims Reserve (Tables)

Claims Reserve (Tables)	6 Months Ended
	Jun. 30, 2019
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]	Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Six Months Ended June 30, Subscription 2019 2018 Reserve at beginning of year $ 13,875 $ 11,059 Veterinary invoices during the period related to: Current year 110,248 91,464 Prior years 551 119 Total veterinary invoice expense 110,799 91,583 Amounts paid during the period related to: Current year 97,165 80,841 Prior years 11,364 9,256 Total paid 108,529 90,097 Non-cash expenses 369 333 Reserve at end of period $ 15,776 $ 12,212 The Company's reserve for the subscription business segment increased from $13.9 million at December 31, 2018 to $15.8 million at June 30, 2019 . This change was comprised of $110.8 million in expense recorded during the period less $108.5 million in payments of veterinary invoices. The $110.8 million in veterinary invoice expense incurred included an adjustment of $0.6 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2018 , the Company increased prior year reserves by $0.1 million as a result of analysis of payment trends. Summarized below are the changes in total liability for the Company's other business segment (in thousands): Six Months Ended June 30, Other Business 2019 2018 Reserve at beginning of year $ 2,187 $ 1,697 Veterinary invoices during the period related to: Current year 16,747 10,589 Prior years (331 ) (279 ) Total veterinary invoice expense 16,416 10,310 Amounts paid during the period related to: Current year 14,431 8,916 Prior years 1,668 1,307 Total paid 16,099 10,223 Non-cash expenses — — Reserve at end of period $ 2,504 $ 1,784 The Company’s reserve for the other business segment increased from $2.2 million at December 31, 2018 to $2.5 million at June 30, 2019 . This change was comprised of $16.4 million in expense recorded during the period less $16.1 million in payments of veterinary invoices. The $16.4 million in veterinary invoice expense incurred included a reduction of $0.3 million to the reserves relating to prior years, which was the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2018 , the Company decreased prior year reserves by $0.3 million as a result of analysis of payment trends.
IBRN plus expected development on reported claims[Table Text Block]	In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by the year to which the veterinary invoice relates, referred to as the year of occurrence. Subscription As of June 30, 2019 Year of Occurrence 2017 and prior $ 862 2018 2,201 2019 12,713 $ 15,776 Other Business As of June 30, 2019 Year of Occurrence 2017 and prior $ 9 2018 179 2019 2,316 $ 2,504

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and other service providers and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or other service provider. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Veterinary invoice expense $ 185 $ 148 $ 346 $ 268 Other cost of revenue 93 104 179 181 Technology and development 110 60 173 109 General and administrative 918 625 1,536 1,074 Sales and marketing 567 349 996 622 Total stock-based compensation $ 1,873 $ 1,286 $ 3,230 $ 2,254 As of June 30, 2019 , the Company had 323,257 unvested stock options and 715,941 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expenses of $2.2 million related to unvested stock options and $16.2 million related to unvested restricted stock awards and restricted stock units are expected to be recognized over a weighted average period of approximately 1.6 years and 2.7 years, respectively.
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company's stock option activity is as follows: Number of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2018 2,621,503 $ 9.01 $ 43,136 Granted — — — Exercised (361,653 ) 3.65 9,736 Forfeited (5,855 ) 17.79 — Outstanding as of June 30, 2019 2,253,995 9.85 59,245 Exercisable as of June 30, 2019 1,930,738 $ 8.67 $ 53,019 As of June 30, 2019 , stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 5.6 years and 5.2 years, respectively.
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2018 451,160 $ 22.16 Granted 374,348 29.88 Vested (97,735 ) 27.92 Forfeited (11,832 ) 28.07 Unvested shares as of June 30, 2019 715,941 $ 25.31

Stock-based Compensation Stockh

Stock-based Compensation Stockholder's Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Class of Warrant or Right [Line Items]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	During the six months ended June 30, 2019 , outstanding warrants to purchase 480,000 shares of the Company's common stock were exercised. As of June 30, 2019 , no warrants remained outstanding.

Stock-based Compensation Follow

Stock-based Compensation Follow-on Public Offering (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Follow-on Public Offering, June 2018 [Table Text Block]	In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.7 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. The proceeds were primarily used to purchase real estate consisting of properties in use as the Company's home office. In addition, in August 2018, the Company issued 303,030 shares of common stock via a private placement to an accredited investor as a portion of the purchase price of the real estate.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Stockholders' Equity Attributable to Parent [Abstract]
Follow-on Public Offering, June 2018 [Table Text Block]	In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.7 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. The proceeds were primarily used to purchase real estate consisting of properties in use as the Company's home office. In addition, in August 2018, the Company issued 303,030 shares of common stock via a private placement to an accredited investor as a portion of the purchase price of the real estate.
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	During the six months ended June 30, 2019 , outstanding warrants to purchase 480,000 shares of the Company's common stock were exercised. As of June 30, 2019 , no warrants remained outstanding.

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Revenue and Gross Profit from Segments [Table Text Block]	Revenue and gross profit of the Company’s segments were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Revenue: Subscription business $ 77,736 $ 63,867 $ 151,958 $ 125,384 Other business 14,463 9,525 27,219 17,768 92,199 73,392 179,177 143,152 Veterinary invoice expense: Subscription business 57,161 46,446 110,799 91,583 Other business 8,772 5,334 16,416 10,310 65,933 51,780 127,215 101,893 Other cost of revenue: Subscription business 7,103 5,887 13,852 11,764 Other business 4,450 3,372 8,365 6,078 11,553 9,259 22,217 17,842 Gross profit: Subscription business 13,472 11,534 27,307 22,037 Other business 1,241 819 2,438 1,380 14,713 12,353 29,745 23,417 Technology and development 2,578 2,298 5,247 4,462 General and administrative 5,219 4,610 10,638 9,068 Sales and marketing: Subscription business 8,719 5,614 16,816 11,465 Other business 38 88 168 175 8,757 5,702 16,984 11,640 Gain (loss) from investment in joint venture (272 ) — (272 ) — Operating loss $ (2,113 ) $ (257 ) $ (3,396 ) $ (1,753 )
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 United States $ 75,930 $ 59,431 $ 147,087 $ 115,440 Canada 16,269 13,961 32,090 27,712 Total revenue $ 92,199 $ 73,392 $ 179,177 $ 143,152

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details) Narrative $ in Millions	Jun. 30, 2019USD ($)
Organization and Basis of Presentation [Line Items]
Operating Lease, Right-of-Use Asset	$ 0.1

Net Loss per Share (Details) Sc

Net Loss per Share (Details) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,253,995	3,696,242	2,253,995	3,696,242
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	715,941	555,984	715,941	555,984
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	480,000	0	480,000

Net Loss per Share Computation

Net Loss per Share Computation of Net Income (Loss) Per Share (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Schedule of Earnings Per Share, Basic and Diluted [Line Items]
Net Income (Loss) Available to Common Stockholders, Basic	$ (1,931)	$ (377)	$ (3,227)	$ (1,857)

Investment Securities (Details)

Investment Securities (Details) Investment Schedule - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Investment [Line Items]
Available-for-sale securities, amortized cost	$ 3,891
Available-for-sale Securities, Gross Unrealized Gain	0	$ 0
Available-for-sale Securities, Gross Unrealized Loss	0	(19)
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Amortized Cost	3,891	3,573
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	3,891	3,554
Short-term investments, amortized cost	64,712	54,559
Short-term Investments, Gross Unrealized Holding Gains	4	0
Short-term investments, gross unrealized holding losses	0	(3)
Short-term Investments, fair value	64,716	54,556
Deposits [Member]
Investment [Line Items]
Available-for-sale securities, amortized cost	2,891	2,573
Available-for-sale Securities, Gross Unrealized Gain	0	0
Available-for-sale Securities, Gross Unrealized Loss	0	0
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	2,891	2,573
Municipal Bonds [Member]
Investment [Line Items]
Available-for-sale securities, amortized cost	1,000	1,000
Available-for-sale Securities, Gross Unrealized Gain	0	0
Available-for-sale Securities, Gross Unrealized Loss	0	(19)
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	1,000	981
U.S. Treasury securities
Investment [Line Items]
Short-term investments, amortized cost	6,140	6,645
Short-term Investments, Gross Unrealized Holding Gains	4	0
Short-term investments, gross unrealized holding losses	0	(3)
Short-term Investments, fair value	6,144	6,642
Certificates of deposit
Investment [Line Items]
Short-term investments, amortized cost	439	437
Short-term Investments, Gross Unrealized Holding Gains		0
Short-term investments, gross unrealized holding losses	0	0
Short-term Investments, fair value	439	437
US government debt securities
Investment [Line Items]
Short-term investments, amortized cost	58,133	47,477
Short-term Investments, Gross Unrealized Holding Gains	0	0
Short-term investments, gross unrealized holding losses	0	0
Short-term Investments, fair value	$ 58,133	$ 47,477

Investment Securities (Detail_2

Investment Securities (Details) Available-for-Sale - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Abstract]
Available-for-sale securities, debt maturities, year two through five, amortized cost basis	$ 3,891
Available-for-sale securities, debt maturities, year two through five, fair value	3,891
Available-for-sale securities, amortized cost	3,891	$ 3,573
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	$ 3,891	$ 3,554

Other Investments (Details)

Other Investments (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Investments, All Other Investments [Abstract]
Purchase of Equity Interest	$ 3
Other Commitment	2.2
Investment Company, Committed Capital	4
Increase (Decrease) in Notes Receivables	2.5
Loans Receivable, Net	2.1	$ 0.6
Payments to Acquire Interest in Joint Venture	$ 0.3

Fair Value (Details) Unobservab

Fair Value (Details) Unobservable - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	$ 1,400,000	$ 1,400,000
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	3,891,000	3,554,000
Noncontrolling Interest in Variable Interest Entity	3,000,000	3,000,000
Assets, Fair Value Disclosure	10,329,000	9,964,000
Notes Receivable, Fair Value Disclosure	4,400,000	3,000,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	0	0
Assets, Fair Value Disclosure	6,329,000	5,983,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	0	0
Assets, Fair Value Disclosure	1,000,000	981,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncontrolling Interest in Variable Interest Entity	3,000,000	3,000,000
Assets, Fair Value Disclosure	3,000,000	3,000,000
Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	1,400,000	1,400,000
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	1,400,000	1,400,000
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	0	0
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Cash	0	0
Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	2,891,000	2,573,000
Cash and Cash Equivalents, Fair Value Disclosure	2,038,000	2,010,000
Deposits [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	2,891,000	2,573,000
Cash and Cash Equivalents, Fair Value Disclosure	2,038,000	2,010,000
Deposits [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	0	0
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Deposits [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	0	0
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Municipal bond
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	1,000,000	981,000
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	1,000,000	981,000
Municipal bond | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	0	0
Municipal bond | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	1,000,000	981,000
Municipal bond | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value	$ 0	$ 0

Fair Value (Details) Narrative

Fair Value (Details) Narrative - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Note Receivable, Fair Value [Abstract]
Notes Receivable, Fair Value Disclosure	$ 4.4	$ 3

Debt (Details) Narrative

Debt (Details) Narrative $ in Millions	6 Months Ended
	Jun. 30, 2019USD ($)
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity	$ 50
Line of credit facility, interest rate description	greater of 4.5%, or 0.75% plus the prime rate
Line of Credit Facility, Interest Rate During Period	6.25%
Line of Credit Facility, Ancillary Services and Letter of Credit	$ 4.5
Restricted Cash and Cash Equivalents	1.4
Line of Credit Facility, Remaining Borrowing Capacity	30.3
Line of Credit Facility, Ancillary Services and Letter of Credit	0.5
Long-term Line of Credit	19.2
Line of Credit Financing Fee	$ 0.1

Commitment and Contingencies Ob

Commitment and Contingencies Obligation for VIE (Details) $ in Millions	6 Months Ended
	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Investment Company, Committed Capital	$ 4

Claims Reserve (Details) Claims

Claims Reserve (Details) Claims Loss Roll-forward - Other business - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Claims Reserve	$ 2,504	$ 1,784	$ 2,187	$ 1,697
Current Year Claims Incurred	16,747	10,589
Prior Year Claims Incurred	(331)	(279)
Total Claims Incurred	16,416	10,310
Current Year Claims Paid	14,431	8,916
Prior Years Claims Paid	1,668	1,307
Total Claims Paid	16,099	10,223
Claims expense non-cash	0	$ 0
Claims Reserve by Loss Year
Incurred but Not Reported (IBNR) Claims Liability	2,504
Short-duration Insurance Contracts, Accident Year 2017 [Member]
Claims Reserve by Loss Year
Incurred but Not Reported (IBNR) Claims Liability	9
Shortduration insurance contracts for accident year 2018 [Member]
Claims Reserve by Loss Year
Incurred but Not Reported (IBNR) Claims Liability	179
Short-duration Insurance Contracts, Accident Year 2019 [Member]
Claims Reserve by Loss Year
Incurred but Not Reported (IBNR) Claims Liability	$ 2,316

Claims Reserve (Details) Narrat

Claims Reserve (Details) Narrative - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Subscription business
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Claims Reserve	$ 15,776	$ 12,212	$ 13,875	$ 11,059
Total Claims Incurred	110,799	91,583
Total Claims Paid	108,529	90,097
Prior Year Claims Incurred	551	119
Other business
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]
Claims Reserve	2,504	1,784	$ 2,187	$ 1,697
Total Claims Incurred	16,416	10,310
Total Claims Paid	16,099	10,223
Prior Year Claims Incurred	$ (331)	$ (279)

Claims Reserve Claims Reserve_2

Claims Reserve Claims Reserve (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 15,776
Claims Reserve	15,776	$ 12,212	$ 13,875	$ 11,059
Current Year Claims Incurred	110,248	91,464
Prior Year Claims Incurred	551	119
Current Year Claims Paid	97,165	80,841
Prior Years Claims Paid	11,364	9,256
Total Claims Paid	108,529	90,097
Claims expense non-cash	369	333
Total Claims Incurred	110,799	91,583
Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	2,504
Claims Reserve	2,504	1,784	$ 2,187	$ 1,697
Current Year Claims Incurred	16,747	10,589
Prior Year Claims Incurred	(331)	(279)
Current Year Claims Paid	14,431	8,916
Prior Years Claims Paid	1,668	1,307
Total Claims Paid	16,099	10,223
Claims expense non-cash	0	0
Total Claims Incurred	16,416	$ 10,310
Short-duration Insurance Contracts, Accident Year 2017 [Member] | Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	862
Short-duration Insurance Contracts, Accident Year 2017 [Member] | Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	9
Shortduration insurance contracts for accident year 2018 [Member] | Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	2,201
Shortduration insurance contracts for accident year 2018 [Member] | Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	179
Short-duration Insurance Contracts, Accident Year 2019 [Member] | Subscription business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	12,713
Short-duration Insurance Contracts, Accident Year 2019 [Member] | Other business
Liability for Claims and Claims Adjustment Expense [Line Items]
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 2,316

Stock-based Compensation (Detai

Stock-based Compensation (Details) Expense Category - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 1,873	$ 1,286	$ 3,230	$ 2,254
Claims expense
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	185	148	346	268
Other Cost of Revenue
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	93	104	179	181
Technology and development
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	110	60	173	109
General and administrative
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	918	625	1,536	1,074
Sales and marketing
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	567	$ 349	$ 996	$ 622
Restricted Stock Units (RSUs) [Member]
Stock-based Compensation
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period			2 years 8 months 12 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 16,200		$ 16,200
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	715,941		715,941
Employee Stock Option [Member]
Stock-based Compensation
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period			1 year 7 months 6 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 2,200		$ 2,200
Employee share-based compensation arrangement by share-based payment award, options, nonvested, number of shares	323,257		323,257

Stock-based Compensation (Det_2

Stock-based Compensation (Details) Options Granted, Exercised and Forfeited - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation, options, outstanding, number of shares	2,253,995	2,621,503
Stock-based compensation, options, granted, number of options	0
Stock-based compensation, options, exercised	(361,653)
Stock-based compensation, options, forfeited	(5,855)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,930,738
Stock-based compensation, options, outstanding, weighted-average exercise price	$ 9.85	$ 9.01
Stock-based compensation, options, granted, weighted-average exercise price	0
Stock-based compensation, options, exercised, weighted-average exercise price	3.65
Stock-based compensation, options, forfeited, weighted-average exercise price	17.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 8.67
Stock-based compensation, options, outstanding, aggregate intrinsic value	$ 59,245	$ 43,136
Stock-based compensation, options, exercised, aggregate intrinsic value	9,736
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 53,019
Remaining contractual life, share-based payments, weighted average	5 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	5 years 2 months 12 days

Stock-based Compensation Restri

Stock-based Compensation Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	715,941	451,160
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	374,348
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(11,832)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(97,735)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 25.31	$ 22.16
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	29.88
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	28.07
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 27.92

Stock-based Compensation Stoc_2

Stock-based Compensation Stockholder Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Stockholders' Equity Attributable to Parent [Abstract]
Stock Issued During Period, Shares, New Issues			2,090,909
Redemption of warrants	480,000
Common Stock, Shares, Issued to Underwriter			272,727
Shares Issued, Price Per Share			$ 33
Proceeds from Issuance or Sale of Equity	$ 0	$ 65,886	$ 65,700
Common Stock, Shares, Issued via Private Placement			303,030

Leases (Details)

Leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Leases [Abstract]
Operating Lease, Right-of-Use Asset	$ 100
Proceeds from Rents Received	1,100
Operating Leases, Future Minimum Payments Receivable, Current	1,071
Operating Leases, Future Minimum Payments Receivable, in Two Years	1,982
Operating Leases, Future Minimum Payments Receivable, in Three Years	1,558
Operating Leases, Future Minimum Payments Receivable, in Four Years	1,173
Operating Leases, Future Minimum Payments Receivable, in Five Years	1,210
Operating Leases, Future Minimum Payments Receivable, Thereafter	2,762
Operating Leases, Future Minimum Payments Receivable	$ 9,756

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, Shares Authorized	100,000,000		100,000,000
Common Stock, Shares, Outstanding	34,782,324		34,025,136
Preferred Stock, Shares Authorized	10,000,000		10,000,000
Stock Issued During Period, Shares, New Issues			2,090,909
Common Stock, Shares, Issued to Underwriter			272,727
Shares Issued, Price Per Share			$ 33
Proceeds from Issuance or Sale of Equity	$ 0	$ 65,886	$ 65,700
Common Stock, Shares, Issued via Private Placement			303,030
Redemption of warrants	480,000

Segments (Details) Business Seg

Segments (Details) Business Segment - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenue	$ 92,199	$ 73,392	$ 179,177	$ 143,152
Veterinary invoice expense	65,933	51,780	127,215	101,893
Other Cost of Services Sold	11,553	9,259	22,217	17,842
Gross profit	14,713	12,353	29,745	23,417
Operating Expenses	16,554	12,610	32,869	25,170
Technology and Development Expense	2,578	2,298	5,247	4,462
General and administrative	5,219	4,610	10,638	9,068
Sales and marketing	8,757	5,702	16,984	11,640
Income (Loss) from Equity Method Investments	(272)		(272)
Operating loss	(2,113)	(257)	(3,396)	(1,753)
Subscription business
Segment Reporting Information [Line Items]
Revenue	77,736	63,867	151,958	125,384
Veterinary invoice expense	57,161	46,446	110,799	91,583
Other Cost of Services Sold	7,103	5,887	13,852	11,764
Gross profit	13,472	11,534	27,307	22,037
Sales and marketing	8,719	5,614	16,816	11,465
Other business
Segment Reporting Information [Line Items]
Revenue	14,463	9,525	27,219	17,768
Veterinary invoice expense	8,772	5,334	16,416	10,310
Other Cost of Services Sold	4,450	3,372	8,365	6,078
Gross profit	1,241	819	2,438	1,380
Sales and marketing	$ 38	$ 88	$ 168	$ 175

Segments (Details) Revenue by G

Segments (Details) Revenue by Geography - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenues	$ 92,199	$ 73,392	$ 179,177	$ 143,152
CANADA
Segment Reporting Information [Line Items]
Revenues	16,269	13,961	32,090	27,712
UNITED STATES
Segment Reporting Information [Line Items]
Revenues	$ 75,930	$ 59,431	$ 147,087	$ 115,440